Ziihera (zanidatamab-hrii)
Antineoplastic Monoclonal Antibodies Intravenous Vial (Ea)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Zanidatamab-hrii, a humanized, immunoglobulin G (IgG)-like, bispecific anti-human epidermal growth factor receptor 2 (anti-HER2) antibody, is an antineoplastic agent.
Zanidatamab-hrii, a humanized, IgG-like, bispecific, anti-HER2 antibody, is an antineoplastic agent. Zanidatamab-hrii is produced by recombinant DNA technology in a mammalian cell (Chinese hamster ovary) culture. Zanidatamab-hrii binds to 2 extracellular sites on HER2 (the dimerisation domain and the extracellular juxtamembrane domain), resulting in the formation of receptor-antibody clusters, receptor internalization, and subsequent downregulation of the HER2 receptor on the tumor cell surface.
Zanidatamab-hrii induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), resulting in tumor growth inhibition and cell death in vitro and in vivo.
Peak plasma concentrations of zanidatamab-hrii are dose proportional, and the total systemic exposure is greater than dose proportional with increasing doses. Zanidatamab-hrii is expected to be metabolized into small peptides by catabolic pathways. The mean plasma half-life of zanidatamab-hrii is approximately 21 days.
Age (24-88 years), sex, race (White and Asian), mild and moderate renal impairment (eGFR 30-89 mL/minute estimated using the CKD-EPI), mild hepatic impairment (total bilirubin <= ULN and AST > ULN or total bilirubin between 1-1.5 times the ULN and any AST) or body weight (35-128 kg) do not have clinically important effects on the pharmacokinetics of zanidatamab-hrii.
USES: This medication is used to treat certain types of cancer (biliary tract, esophageal, stomach). Zanidatamab belongs to a class of drugs known as monoclonal antibodies. Zanidatamab works by slowing or stopping the growth of cancer cells.
Generic name: zanidatamab-hrii
Drug class: Antineoplastic Monoclonal Antibodies
Therapeutic class: Antineoplastics
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Ziihera
Indications
The following indications are listed for Ziihera:
- Her2-Positive Adenocarcinoma Of Gastroesophageal Junction
- Her2-Positive Biliary Tract Malignancy
- Her2-Positive Esophageal Adenocarcinoma
- Her2-Positive Gastric Adenocarcinoma
Also known as: Her-2 Overexpressing Adenocarcinoma Of Gastroesophageal Junction, Her-2 Overexpressing Gastroesophageal Junction Adenocarcinoma, Her2-Overexpressing Esophageal Adenocarcinoma, Her2-Overexpressing Gastric Adenocarcinoma, Her2-Positive Adenocarcinoma Of Stomach, Her2-Positive Adenocarcinoma Of The Esophagus, Her2-Positive Gastroesophageal Junction Adenocarcinoma.
Dosing
If adverse events occur during zanidatamab-hrii therapy, temporary interruption of therapy, dosage reduction, and/or discontinuance of the drug may be necessary. In general, if dosage reduction is necessary, the recommended dosage is 15 mg/kg. If a dosage of 15 mg/kg is not tolerated, zanidatamab-hrii should be permanently discontinued.
Administer zanidatamab-hrii via IV infusion in a dedicated line with a low protein-binding 0.2-micron in-line filter. Do not administer via rapid IV bolus injection.
Zanidatamab-hrii is available as a 300-mg single-dose vial of preservative-free lyophilized powder that must be reconstituted and diluted prior to IV infusion.
Do not administer in the same IV line with other medications.
Store vials of zanidatamab-hrii refrigerated at 2-8degreesC in original carton. Do not freeze.
Zanidatamab-hrii is compatible with 0.9% sodium chloride injection and 5% dextrose injection.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Ziihera 300 Mg Vial | Maintenance | Infuse 20 mg/kg by intravenous route every 2 weeks. |
No dosing information is available for this tab.
Drug interactions
No formal drug interaction studies have been conducted to date with zanidatamab-hrii.
There are no contraindication interactions for this drug.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Igg Antibodies And Derivatives/Efgartigimod-Alfa
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Efgartigimod-alfa binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of efgartigimod-alfa states that efgartigimod-alfa should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, efgartigimod-alfa should be discontinued.(3)
DISCUSSION: Clinical drug interaction studies with efgartigimod-alfa have not been performed. Efgartigimod-alfa may decrease concentrations of compounds that bind to the human FcRn.(3)
Igg Antibodies And Derivatives/Nipocalimab-Aahu
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Nipocalimab-aahu binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of nipocalimab-aahu states that nipocalimab-aahu should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, nipocalimab-aahu should be discontinued.(3)
DISCUSSION: Clinical drug interaction studies with nipocalimab-aahu have not been performed. Nipocalimab-aahu may decrease concentrations of compounds that bind to the human FcRn.(3)
Moderate Interaction: Assess the risk to the patient and take action as needed.
Igg Antibodies And Derivatives/Rozanolixizumab-Noli
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Rozanolixizumab-noli binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medications that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of rozanolixizumab-noli states that concurrent use with medications that bind to the human neonatal Fc receptor (FcRn) should be closely monitored for reduced effectiveness of these medications. If long-term use of such medications is essential for the patient, consider discontinuing rozanolixizumab-noli and use alternative therapies.(3)
DISCUSSION: Clinical drug interaction studies with rozanolixizumab-noli have not been performed. Rozanolixizumab-noli may decrease concentrations of compounds that bind to the human FcRn.(3)
Contraindications
*None.
There are no contraindication contraindications for this drug.
- Chronic heart failure
- Pregnancy
There are no moderate contraindications for this drug.
Adverse reactions
The most common adverse reactions (incidence >=20%) reported with zanidatamab-hrii in clinical studies were diarrhea, infusion-related reaction, abdominal pain, and fatigue.
Less Frequent
- Biliary obstruction
- Biliary tract infection
- Gastrointestinal obstruction
- Left ventricular failure
- Pneumonia
- Sepsis
More Frequent
- Acute abdominal pain
- Anemia
- Anorexia
- Diarrhea
- Fatigue
- Hypoalbuminemia
- Hypokalemia
- Hyponatremia
- Increased alkaline phosphatase
- Injection site sequelae
- Lymphopenia
- Nausea
- Skin rash
- Vomiting
Less Frequent
- Increased lactate acid dehydrogenase
Precautions
No enhanced messaging available.
Safety and efficacy of zanidatamab-hrii have not been established in pediatric patients <18 years of age.
There are no human or animal data on zanidatamab-hrii use in pregnant women. However, based on its mechanism of action, zanidatamab-hrii can cause fetal harm when administered to a pregnant woman. Oligohydramnios, fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death have been reported in women receiving an anti-HER2 antibody during pregnancy in postmarketing experience.
Verify the pregnancy status of females of reproductive potential prior to the initiation of zanidatamab-hrii. Advise pregnant women and females of reproductive potential that exposure to zanidatamab-hrii during pregnancy or within 4 months prior to conception can result in fetal harm. Advise females of reproductive potential to use effective contraception while receiving zanidatamab-hrii and for 4 months following the last dose of zanidatamab-hrii.
In women who received zanidatamab during pregnancy or within 4 months prior to conception, monitor for oligohydramnios. If oligohydramnios occurs, perform fetal testing that is appropriate for gestational age and consistent with local standard of care.
It is not known whether zanidatamab-hrii is distributed into human milk. Effects of the drug on breastfed infants or milk production are also not known. However, published data suggest that human IgG is present in human milk but does not enter neonatal or infant circulation in substantial amounts. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for zanidatamab-hrii treatment and any potential adverse effects on the breastfed child from zanidatamab-hrii or the underlying maternal condition. The half-life of zanidatamab-hrii of approximately 21 days, and the washout period of 4 months should also be taken into consideration.
The manufacturer makes no specific recommendations for geriatric patients.
In clinical studies, 49% of 80 patients were >=65 years of age; 3% were >=75 years of age. No overall differences in safety or efficacy were observed between geriatric patients (>=65 years of age) and younger adults (<65 years of age).
ICD codes
| Code | Type | Description |
|---|---|---|
| HEr2-positive adenocarcinoma of gastroesophageal junction | ||
| C16.0 | ICD10CM | Malignant neoplasm of cardia |
| HEr2-positive biliary tract malignancy | ||
| C22.1 | ICD10CM | Intrahepatic bile duct carcinoma |
| C23 | ICD10CM | Malignant neoplasm of gallbladder |
| C24 | ICD10CM | Malignant neoplasm of other and unspecified parts of biliary tract |
| C24.0 | ICD10CM | Malignant neoplasm of extrahepatic bile duct |
| C24.1 | ICD10CM | Malignant neoplasm of ampulla of vater |
| C24.8 | ICD10CM | Malignant neoplasm of overlapping sites of biliary tract |
| C24.9 | ICD10CM | Malignant neoplasm of biliary tract, unspecified |
| HEr2-positive esophageal adenocarcinoma | ||
| C15 | ICD10CM | Malignant neoplasm of esophagus |
| C15.3 | ICD10CM | Malignant neoplasm of upper third of esophagus |
| C15.4 | ICD10CM | Malignant neoplasm of middle third of esophagus |
| C15.5 | ICD10CM | Malignant neoplasm of lower third of esophagus |
| C15.8 | ICD10CM | Malignant neoplasm of overlapping sites of esophagus |
| C15.9 | ICD10CM | Malignant neoplasm of esophagus, unspecified |
| HEr2-positive gastric adenocarcinoma | ||
| C16 | ICD10CM | Malignant neoplasm of stomach |
| C16.0 | ICD10CM | Malignant neoplasm of cardia |
| C16.1 | ICD10CM | Malignant neoplasm of fundus of stomach |
| C16.2 | ICD10CM | Malignant neoplasm of body of stomach |
| C16.3 | ICD10CM | Malignant neoplasm of pyloric antrum |
| C16.4 | ICD10CM | Malignant neoplasm of pylorus |
| C16.5 | ICD10CM | Malignant neoplasm of lesser curvature of stomach, unspecified |
| C16.6 | ICD10CM | Malignant neoplasm of greater curvature of stomach, unspecified |
| C16.8 | ICD10CM | Malignant neoplasm of overlapping sites of stomach |
| C16.9 | ICD10CM | Malignant neoplasm of stomach, unspecified |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.